Drug Search Results
More Filters [+]

AVID-100

Alternative Names: avid-100, avid100, avid 100
Latest Update: 2021-03-24
Latest Update Note: Clinical Trial Update

Product Description

Bristol-Myers Squibb was developing avid-100, an intravenous EGFR inhibitor, for the treatment of EGFR-overexpressing squamous histology non-small cell lung cancer, squamous cell carcinoma of the head and neck, and triple negative breast cancer (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03094169)

Mechanisms of Action: EGFR Inhibitor

Novel Mechanism: No

Modality: Antibody Drug Conjugate

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AVID-100

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Head and Neck Cancer|Squamous Cell Carcinoma|Triple Negative Breast Cancer|Non-Small-Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

AVID100-01

P2

Terminated

Triple Negative Breast Cancer|Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma|Head and Neck Cancer

2020-11-28

55%

Recent News Events